Research and Markets has announced the addition of the "TGF Beta Receptor Type 1 - Pipeline Review, H2 2016" report to their offering.
TGF Beta Receptor Type 1 pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities
Institutes. Our latest report TGF Beta Receptor Type 1, outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/58wj4q/tgf_beta_receptor
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005631/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.